Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Single agent VS-6766 or VS-6766 plus defactinib in KRAS-mutant non-small-cell lung cancer: the RAMP-202 phase II trial.

Future oncology (London, England) - 1 May 2022

Capelletto Enrica, Bironzo Paolo, Denis Louis, Koustenis Andrew, Bungaro Maristella, Novello Silvia

Abstract excerpt

KRAS mutations occur in approximately 30% of lung adenocarcinomas, mainly in codon 12 (83% of cases), p.G12C being the prevalent one (40%), followed by p.G12V and p.G12D (22 and 16%, respectively). Treatment options for advanced KRAS mutant non-small-cell lung cancer (KRAS-MT NSCLC) are limited to chemotherapy and immune checkpoint inhibitors (CPIs). However, clinical trials exploring specific targeted agents are...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials, Phase II as Topic

Share to Lung Neoplasms

Share to Mutation

Share to Proto-Oncogene Proteins p21(ras)

Share to Pyrazines

Share to Sulfonamides

Source

Identifiers

PMID: 35285277
DOI: 10.2217/fon-2021-1582

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Single agent VS-6766 or VS-6766 plus defactinib in KRAS-mutant non-small-cell lung cancer: the RAMP-202 phase II trial.PMID 35285277Read ↗

KRAS-Targeted Therapies in NSCLC: Resistance, Combination Strategies, and Emerging Clinical Paradigms.Semantic proximity Read ↗

The KRAS G12C mutation in NSCLC: from target to resistanceSemantic proximity Read ↗

Literature review of advances and challenges in KRAS G12C mutant non-small cell lung cancerSemantic proximity Read ↗

Targeted therapeutic options in early and metastatic NSCLC-overview.Semantic proximity Read ↗

Decoding KRAS mutation in non-small cell lung cancer patients receiving immunotherapy: A retrospective institutional comparison and literature review.Semantic proximity Read ↗

Targeted Therapies for Previously "Undruggable" KRAS-Mutated Non-Small Cell Lung Cancer: A Review of Sotorasib and Adagrasib.Semantic proximity Read ↗

Recent advances in EGFR-targeted therapies for non-small cell lung cancer.Semantic proximity Read ↗

Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun.Semantic proximity Read ↗

First-line treatments for KRAS-mutant non-small cell lung cancer: current state and future perspectives.Semantic proximity Read ↗

From G12C To pan-RAS: The expanding therapeutic landscape of KRAS-mutant NSCLC.Semantic proximity Read ↗

Cutting edge therapies: A review of Food and Drug Administration-approved drugs for non-small cell lung cancer.Semantic proximity Read ↗

Advances in targeting KRAS mutations: A promising approach for the treatment of non‑small cell lung cancer (Review).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.